Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Selcia Appoints New Director of Discovery

Published: Wednesday, October 09, 2013
Last Updated: Wednesday, October 09, 2013
Bookmark and Share
Appointment of John Davis to the role of Director of Discovery.

Selcia Limited has appointed John Davis to the newly created role of Director of Discovery.

John joins Selcia from Convergence Pharmaceuticals, where he served as Head of Biology between 2010 and 2013 and was a co-founder of the company.

Dr. Hans Fliri, chairman and CEO of Selcia Ltd., said “We are delighted that John has joined Selcia, his extensive drug discovery expertise will be a tremendous asset to our business. We have an ambitious plan to grow and further develop Selcia’s integrated drug discovery service. John’s knowledge of the international pharmaceutical and biotechnology industries will undoubtedly help us achieve that goal.”

John’s particular research interests have been focussed on cardiovascular, oncology and CNS disorders. Much of his 20 years’ drug discovery experience was gained at SmithKline Beecham and GlaxoSmithKline and encompasses a range of target classes including ion channels, GPCRs, kinases and proteases.

With his deep experience of target identification through to clinical proof of concept, John has been responsible for the discovery of 11 small molecule and biologic development candidates, and the preclinical pharmacology supporting two assets achieving positive Phase II and one product.

At GSK John was variously director of neurodegeneration research, a director of discovery technologies and director of biology for pain and epilepsy research, and was also instrumental in the formation and management of several large collaborations with universities.

John originally trained as a biochemist and has a PhD from Cambridge University. He was a research fellow at the Ludwig Institute for Cancer Research and Salk Institute for six years before joining SmithKline Beecham in 1993. He has over 100 peer reviewed publications and patents to his name.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Simon Bury Joins Selcia
Selcia Limited announces the appointment of Simon Bury as Business Development Director of its Discovery division, to lead expansion plans in its drug discovery offering.
Friday, June 03, 2011
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.
Substance Can Potentially Postpone Aging
Researchers bridge the gap between two main aging theories - repairs to the DNA and poor functioning mitochondria.
Untangling Cause Of Memory Loss In Neurodegenerative Diseases
NIH-funded mouse study identifies a possible therapeutic target for a family of disorders.
New Model for Understanding Human Myeloma
Researchers develop mouse model where mice carry six human genes involved in human tumour growth.
Preventing Alzheimer's in Mice
Researchers have prevented the Alzheimer’s development in mice by using a virus delivery system to transport a specific gene into the brain.
New Platform for Roundworms Could Speed Up Drug Delivery
Researchers have developed a large-scale in vitro drug discovery platform that could speed up scientific research.
Scientists Speed Up Muscle Repair
Researchers discovered genetically modified mice were able to support far more regenerative stem cells, for muscle repair, than previously thought.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos